Marxsen J, Schmiegel W, Röder C, Harder R, Juhl H, Henne-Bruns D, Kremer B, Kalthoff H
Klinik für Allgemeine Chirurgie und Thoraxchirurgie, Forschungsgruppe Molekulare Onkologie, Christian-Albrechts-Universität, Kiel, Germany.
Br J Cancer. 1994 Nov;70(5):1031-4. doi: 10.1038/bjc.1994.443.
Genomic alterations in the p53 tumour-suppressor gene and overexpression of p53 protein, resulting from gene mutations, are frequently found in pancreatic cancer. In this study we analysed the sera of 160 patients with malignant and benign pancreatic diseases for the presence of circulating antibodies to the p53 protein. The analysis of the sera was performed using two different enzyme-linked immunosorbent assay (ELISA) systems. To further substantiate the results, all sera were analysed by the Western blot technique using a cell lysate of PancTu-1 cells (p53 mutation at codon 176) as antigen source. Additionally, all positive sera were analysed by the Western blot technique using recombinant p53 as the antigen source. Although the rate of p53 mutations in pancreatic tumours is of the same order as in other adenocarcinomas (> or = 50%), an antibody response was found in only 5/78 (6.4%) sera from patients with pancreatic cancer. Two out of 82 (2.4%) sera of patients with benign pancreatic diseases were clearly positive for p53 antibodies. One additional specimen was weakly positive, i.e. only in one ELISA and Western blot system.
p53肿瘤抑制基因的基因组改变以及由基因突变导致的p53蛋白过表达在胰腺癌中很常见。在本研究中，我们分析了160例患有恶性和良性胰腺疾病患者的血清中是否存在针对p53蛋白的循环抗体。血清分析使用了两种不同的酶联免疫吸附测定（ELISA）系统。为了进一步证实结果，所有血清均采用蛋白质印迹技术进行分析，以PancTu - 1细胞（密码子176处p53突变）的细胞裂解物作为抗原来源。此外，所有阳性血清均采用蛋白质印迹技术进行分析，以重组p53作为抗原来源。尽管胰腺肿瘤中p53突变率与其他腺癌相同（≥50%），但在胰腺癌患者的78份血清中仅5份（6.4%）发现了抗体反应。82例良性胰腺疾病患者的血清中有2份（2.4%）p53抗体呈明显阳性。另有一份标本弱阳性，即在一种ELISA和蛋白质印迹系统中呈阳性。
